decamethonium bromide (syncurine) Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Decamethylene disquaternary salts, with a ten-carbon (C10) chain between the quaternary groups, had the most potent curariform action in the series of polymethylene bisquaternaries. Decamethonium was used clinically as a neuromuscular blocking drug for a short time. Decamethonium was different from d-tubocurarine and that it produced a transient augmentation of contraction. C10 produces neuromuscular block by initiating some active response in the endplate or muscle fibre. Unlike d-tubocurare, decamethonium was not reversed by anticholinesterase agents.   NCATS

Chemistry

More Chemistry

Pharmacology

Alternative names

decamethonium | decamethonium bromide | decamethonium dibromide | decamethonium dichloride | decamethonium dihydroxide | decamethonium diiodide | decamethonium dipricrate | decamethonium iodide | decamethonium ion | decamethonum | decamethylenebis(trimethylammonium) | decamethylenebis(trimethylammonium)bromide | (dm)br2 | n,n,n,n',n',n'-hexamethyl-1,10-decanediaminium | syncurine

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Muscle Contraction

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue